ArticleArchives of medical science : AMS2025
Causal associations between blood metabolites and breast cancer.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluating the causal relationship between sex hormones and oral cavity cancer: a Mendelian randomization study.Archives of medical science : AMS · 2026Article
- The causal effects of 1400 genetically determined human blood metabolites and metabolite ratios on the risk of gastrointestinal tumors: a Mendelian randomization study.Archives of medical science : AMS · 2026Article
- Global burden and developments in pre- and post-menopausal estrogen-related cancer from 1990 to 2021, with estimates for 2035.Archives of medical science : AMS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The associations between blood metabolites and breast cancer remain unclear. We conducted a systematic two-sample Mendelian randomization (MR) analysis to identify key human blood metabolites and potential biomarkers for breast cancer development. Material and methods: The data were extracted from large-scale genome-wide association study (GWAS) public databases. Instrumental variables were selected from a cohort study of 453 metabolic profiles from 7,824 participants. Breast cancer incidence data were obtained from a large cohort study involving 138,389 cases and 240,341 controls. Causal associations between human blood metabolites and breast cancer incidence were assessed using inverse-variance weighting, and MR-Egger regression. Results: Five human blood metabolites were identified as biomarkers for breast cancer: serine (OR = 2.25; 95% CI: 1.18-4.27), 10-undecenoate (11:1n1) (OR = 1.38; 95% CI: 1.00-1.90), X-12696 (OR = 2.15; 95% CI: 1.14-4.08), X-14626 (OR = 1.68; 95% CI: 1.15-2.46), and succinyl carnitine (OR = 1.58; 95% CI: 1.06-2.34). The sensitivity analysis results indicate no pleiotropy between the metabolites and breast cancer risk, confirming the robustness of the findings. Conclusions: This study in metabolomics research identified five human blood metabolites - serine, 10-undecenoate (11:1n1), X-12696, X-14626, and succinylcarnitine - as potential biomarkers for assessing breast cancer risk. Among these metabolites, serine and X-12696 showed the strongest associations with the likelihood of developing breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.